Pharmaceutical intermediates
Resmetirom Intermediates
7 pharmaceutical intermediates for Resmetirom. Indication: Non-Alcoholic Steatohepatitis (NASH); Liver Cirrhosis.
About Resmetirom
- Originator
- Roche
- Indication
- Non-Alcoholic Steatohepatitis (NASH); Liver Cirrhosis
- Approved Date
- 03/14/2024
- NCE Patent
- 03/14/2029
- DS/DP
- 09/12/2026
Available intermediates
7 intermediates currently listed for Resmetirom. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 6-(4-amino-2,6-dichlorophenoxy)-4-isopropylpyridazin-3(2H)-one | 920509-28-0 | / | / |
| 3,6-dichloro-4-isopropylpyridazine | 107228-51-3 | / | / |
| 4-(Propan-2-yl)pyridazine-3,6-diol | 1903632-97-2 | / | / |
| 3,5-dichloro-4-((6-chloro-5-isopropylpyridazin-3-yl)oxy)aniline(WXG00196) | 920509-27-9 | / | / |
| 3,6-Dichloropyridazine | 141-30-0 | / | / |
| 4-Amino-2,6-dichlorophenol | 5930-28-9 | / | / |
| N-CYANOACETYLURETHANE | 6629-04-5 | / | / |
Other programs under R
Building toward Resmetirom?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →